Physician profile
Rabia Arshad
NPI 1710927702
$6,177.75
in general payments reported to CMS, 2019-2025
29 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $341 · 2021: $366 · 2022: $722 · 2023: $1,601 · 2024: $1,022 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,770.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,034.32 | 2019-2024 | Aveir, Amplatzer Amulet, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $607.46 | 2020-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $498.49 | 2021-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $364.70 | 2022-2024 | Xarelto |
| Pfizer INC. | $351.06 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $322.41 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $317.01 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $308.64 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $272.36 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $245.94 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $205.72 | 2023-2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $172.32 | 2025 | Attruby |
| Scpharmaceuticals INC. | $165.55 | 2025 | |
| Amarin Pharma, INC. | $150.02 | 2019 | |
| Medtronic Vascular, INC. | $148.14 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $136.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.56 | 2024-2025 | Jardiance |
| Atricure, INC. | $134.46 | 2022 | |
| Medtronic, INC. | $130.56 | 2023 | Claria Mri Quad Crt-D Surescan |
| Lilly USA, LLC | $124.51 | 2025 | |
| Esperion Therapeutics, INC. | $82.06 | 2022-2025 | Nexletol |
| Philips North America LLC | $71.78 | 2020-2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $57.78 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $34.37 | 2020-2023 | Brilinta |
| Recor Medical INC | $28.00 | 2025 | Paradise Ultrasound Renal Denervation System |
| Daiichi Sankyo INC. | $25.00 | 2024 | Injectafer |
| Abiomed | $19.22 | 2024 | Impella |
| Cardiofocus, INC. | $17.70 | 2019 | |
| Cvrx, INC. | $17.22 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabia Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.